Targeted cancer stem cell therapies start with proper identification of the target.
Erina
E
Vlashi
Frank
F
Pajonk
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D018929:Cell Culture Techniques; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology* / Q000627:therapeutic use; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D010641:Phenotype; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects / Q000378:metabolism; D015203:Reproducibility of Results
D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; C063261:acetylleucyl-leucyl-norleucinal; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease